Key result
Diuretic therapy is linked to a ~113% increase in FVC in ischemic heart failure patients.
Why the study?
Does the combination of bumetanide and spironolactone improve spirometric parameters (FVC and FEV1) in patients with ischemic heart failure?
Cohort (n=26)
No
Does the combination of bumetanide and spironolactone improve spirometric parameters (FVC and FEV1) in patients with ischemic heart failure?
Treatment with diuretics significantly improves restrictive spirometric defects (FVC and FEV1) in patients with ischemic heart failure, suggesting office spirometry could be a useful tool for monitoring heart failure deterioration.
Answers are grounded in this paper and cite their sources.
Should not yet change diuretic or monitoring practices in ischemic HF; leaves open confirmation of spirometric benefits versus prior low-certainty evidence.
Heart failure is the failure of the cardiac pump under physiological loading conditions to impart sufficient hydraulic energy output in order to maintain a physiological circulation. A cohort study extended over a period of 14 months from the first of august 2010 to the first of November 2011. The patient was diagnosed as having heart failure according to the recommendation of the European Society of Cardiology, depending on the result of history, examination and echocardiographic conformation. Spirometric data were collected in accordance with American Thoracic Society standards. All the patients had a restrictive spirometric defect before treatment with diuretics, but after treatment all show normal spirometric pattern. The present study recommend the followings: - The use of a cheap office spirometer in rural area by general practitioner (GP) doctors and nursing staff could be useful for follow up patients with ischemic heart failure to detect early deterioration by objective mean to refer the patient for specialized care. Also, the office spirometer needs no special skills and the nursing staff can master the procedure with a 2 weeks training course.
No takes yet. Share an insight, caveat, or question.
Aldaghir et al. (2023) conducted a cohort in Ischemic heart failure (n=26). Diuretics (Bumetanide and Spironolactone) vs. Baseline (before treatment) was evaluated on Forced Vital Capacity (FVC) % of predicted value (p=0.01). Diuretic therapy significantly improved Forced Vital Capacity from 41.46% to 88.38% of predicted value in patients with ischemic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: